Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bemnifosbuvir-Ruzasvir

Phase 3Small molecule

AAtea Pharmaceuticals, Inc.

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

HEPATITIS C VIRUS CHRONIC INFECTIONActive, not recruiting

HEPATITIS C VIRUS CHRONIC INFECTIONPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Efficacy and Safety

NCT06868264

Q1 2027

Phase 3Active, not recruiting

HEPATITIS C VIRUS CHRONIC INFECTION

NCT07037277

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Active, not recruiting·AAtea Pharmaceuticals, Inc.·Phase 3·NCT06868264·880 enrolled

HEPATITIS C VIRUS CHRONIC INFECTION1 trial

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Active, not recruiting·AAtea Pharmaceuticals, Inc.·Phase 3·NCT07037277·880 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bemnifosbuvir-Ruzasvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bemnifosbuvir-Ruzasvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bemnifosbuvir-Ruzasvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atea Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAtea Pharmaceuticals, Inc.

Related News